Logo image of KROS

KEROS THERAPEUTICS INC (KROS) Stock Fundamental Analysis

NASDAQ:KROS - Nasdaq - US4923271013 - Common Stock - Currency: USD

14.3  +0.23 (+1.63%)

After market: 14.3 0 (0%)

Fundamental Rating

4

Taking everything into account, KROS scores 4 out of 10 in our fundamental rating. KROS was compared to 568 industry peers in the Biotechnology industry. KROS has a great financial health rating, but its profitability evaluates not so good. KROS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KROS had negative earnings in the past year.
In the past year KROS has reported a negative cash flow from operations.
KROS had negative earnings in each of the past 5 years.
In the past 5 years KROS always reported negative operating cash flow.
KROS Yearly Net Income VS EBIT VS OCF VS FCFKROS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of KROS (-30.42%) is better than 66.73% of its industry peers.
KROS has a Return On Equity of -32.78%. This is in the better half of the industry: KROS outperforms 75.53% of its industry peers.
Industry RankSector Rank
ROA -30.42%
ROE -32.78%
ROIC N/A
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
KROS Yearly ROA, ROE, ROICKROS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

KROS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KROS Yearly Profit, Operating, Gross MarginsKROS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

KROS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KROS has been increased compared to 1 year ago.
KROS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KROS Yearly Shares OutstandingKROS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KROS Yearly Total Debt VS Total AssetsKROS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

KROS has an Altman-Z score of 6.40. This indicates that KROS is financially healthy and has little risk of bankruptcy at the moment.
KROS has a Altman-Z score of 6.40. This is amongst the best in the industry. KROS outperforms 84.86% of its industry peers.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.4
ROIC/WACCN/A
WACC10.21%
KROS Yearly LT Debt VS Equity VS FCFKROS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

KROS has a Current Ratio of 21.45. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
KROS has a Current ratio of 21.45. This is amongst the best in the industry. KROS outperforms 96.13% of its industry peers.
KROS has a Quick Ratio of 21.45. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
KROS has a better Quick ratio (21.45) than 96.13% of its industry peers.
Industry RankSector Rank
Current Ratio 21.45
Quick Ratio 21.45
KROS Yearly Current Assets VS Current LiabilitesKROS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

KROS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.65%.
Looking at the last year, KROS shows a very strong growth in Revenue. The Revenue has grown by 2220.26%.
Measured over the past years, KROS shows a very negative growth in Revenue. The Revenue has been decreasing by -18.71% on average per year.
EPS 1Y (TTM)3.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.93%
Revenue 1Y (TTM)2220.26%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%2027.27%

3.2 Future

The Earnings Per Share is expected to grow by 9.60% on average over the next years. This is quite good.
KROS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 189.60% yearly.
EPS Next Y27.48%
EPS Next 2Y6.7%
EPS Next 3Y4.57%
EPS Next 5Y9.6%
Revenue Next Year745.9%
Revenue Next 2Y293.94%
Revenue Next 3Y204.66%
Revenue Next 5Y189.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KROS Yearly Revenue VS EstimatesKROS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
KROS Yearly EPS VS EstimatesKROS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KROS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KROS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KROS Price Earnings VS Forward Price EarningsKROS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KROS Per share dataKROS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.7%
EPS Next 3Y4.57%

More info and screens

0

5. Dividend

5.1 Amount

KROS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEROS THERAPEUTICS INC

NASDAQ:KROS (4/21/2025, 8:26:55 PM)

After market: 14.3 0 (0%)

14.3

+0.23 (+1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners102.03%
Inst Owner Change-0.04%
Ins Owners0.63%
Ins Owner Change7.64%
Market Cap580.01M
Analysts80
Price Target31.62 (121.12%)
Short Float %10.84%
Short Ratio2.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.87%
Min EPS beat(2)-13.69%
Max EPS beat(2)-8.05%
EPS beat(4)2
Avg EPS beat(4)-2.32%
Min EPS beat(4)-13.69%
Max EPS beat(4)11.93%
EPS beat(8)5
Avg EPS beat(8)-0.58%
EPS beat(12)7
Avg EPS beat(12)0.43%
EPS beat(16)8
Avg EPS beat(16)2.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.8%
PT rev (3m)-32.61%
EPS NQ rev (1m)-52.94%
EPS NQ rev (3m)82.83%
EPS NY rev (1m)26.44%
EPS NY rev (3m)30.88%
Revenue NQ rev (1m)29.7%
Revenue NQ rev (3m)10816.7%
Revenue NY rev (1m)24.39%
Revenue NY rev (3m)8316.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 163.38
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-5.01
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-4.01
FCFYN/A
OCF(TTM)-3.97
OCFYN/A
SpS0.09
BVpS14.09
TBVpS14.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.42%
ROE -32.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.12%
Cap/Sales 54.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.45
Quick Ratio 21.45
Altman-Z 6.4
F-Score6
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)214.84%
Cap/Depr(5y)203.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.93%
EPS Next Y27.48%
EPS Next 2Y6.7%
EPS Next 3Y4.57%
EPS Next 5Y9.6%
Revenue 1Y (TTM)2220.26%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%2027.27%
Revenue Next Year745.9%
Revenue Next 2Y293.94%
Revenue Next 3Y204.66%
Revenue Next 5Y189.6%
EBIT growth 1Y-24.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.94%
EBIT Next 3Y16.61%
EBIT Next 5YN/A
FCF growth 1Y-28.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.2%
OCF growth 3YN/A
OCF growth 5YN/A